New drug aims to tame cortisol overload from adrenal tumors
NCT ID NCT04308590
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tested a drug called relacorilant in 137 people with hypercortisolism caused by adrenal adenomas or hyperplasia. The goal was to see if it could improve blood sugar control and lower high blood pressure. Participants received either relacorilant or a placebo for a set period, and researchers measured changes in blood pressure and glucose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
relacorilant
What this could lead to
If successful, relacorilant could offer a new treatment option to control blood sugar and blood pressure in people with hypercortisolism.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove effective or could have side effects. It is not a cure and requires ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCORTISOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 01
Wilmington, North Carolina, 28401, United States
-
Site 02
Summerville, South Carolina, 29485, United States
-
Site 03
El Paso, Texas, 79935, United States
-
Site 05
Fort Worth, Texas, 76132, United States
-
Site 06
Jackson, Mississippi, 39202, United States
-
Site 07
Atlanta, Georgia, 30318, United States
-
Site 08
Houston, Texas, 77079, United States
-
Site 09
Metairie, Louisiana, 70006, United States
-
Site 10
Jamaica, New York, 11432, United States
-
Site 11
Fall River, Massachusetts, 02721, United States
-
Site 13
Seville, 41013, Spain
-
Site 14
Málaga, 29006, Spain
-
Site 15
Spokane, Washington, 99202, United States
-
Site 16
Indianapolis, Indiana, 46202, United States
-
Site 17
Stanford, California, 94305, United States
-
Site 20
Dallas, Texas, 75390, United States
-
Site 21
Columbus, Ohio, 43201-3209, United States
-
Site 22
Sofia, 01431, Bulgaria
-
Site 23
Tel Aviv, Israel
-
Site 25
Vienna, State of Vienna, 1090, Austria
-
Site 26
Valencia, 46026, Spain
-
Site 27
Birmingham, Alabama, 35294, United States
-
Site 28
Naples, 80131, Italy
-
Site 30
Cleveland, Ohio, 44195, United States
-
Site 31
Rome, Roma, 00189, Italy
-
Site 32
Ramat Gan, 5265601, Israel
-
Site 33
Rochester, Minnesota, 55905, United States
-
Site 34
Milan, Italy
-
Site 35
Lublin, Poland
-
Site 36
Baltimore, Maryland, 21287, United States
-
Site 37
Rome, 00161, Italy
-
Site 38
Bucharest, 011863, Romania
-
Site 40
Milan, Milano, 20122, Italy
-
Site 41
Bucharest, 011863, Romania
-
Site 42
Bucharest, 010825, Romania
-
Site 43
Orbassano, Torino, Italy
-
Site 44
New York, New York, 10021, United States
-
Site 46
Würzburg, 97080, Germany
-
Site 47
Krakow, 31-501, Poland
-
Site 48
Gliwice, 44-102, Poland
-
Site 50
Munich, Bavaria, 80336, Germany
-
Site 51
Padova, 35128, Italy
-
Site 52
Torino, 10126, Italy
-
Site 53
Torrance, California, 90502, United States
-
Site 54
Reno, Nevada, 89511, United States